Research and Markets has announced the addition of the "Herpes Zoster (Shingles) - Pipeline Review, H2 2016" report to their offering.
Herpes Zoster (Shingles) pipeline therapeutics constitutes close to 15 molecules. Out of which approximately 15 molecules are developed by Companies. The molecules developed by Companies in Phase III, Phase II, Preclinical and Unknown stages are 4, 2, 7 and 2 respectively.
Herpes Zoster (Shingles) - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Herpes Zoster (Shingles), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Herpes Zoster (Shingles) and features dormant and discontinued projects.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/bqqdpc/herpes_zoster
View source version on businesswire.com: http://www.businesswire.com/news/home/20161027006396/en/Business Wire
Last updated on: 27/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.